IN2014DN11157A - - Google Patents

Info

Publication number
IN2014DN11157A
IN2014DN11157A IN11157DEN2014A IN2014DN11157A IN 2014DN11157 A IN2014DN11157 A IN 2014DN11157A IN 11157DEN2014 A IN11157DEN2014 A IN 11157DEN2014A IN 2014DN11157 A IN2014DN11157 A IN 2014DN11157A
Authority
IN
India
Prior art keywords
vegf
against human
ang
mutations
antibodies
Prior art date
Application number
Inventor
Harald Duerr
Frank Herting
Christian Klein
Joerg Thomas Regula
Matthias Rueth
Kay Gunnar Stubenrauch
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48783248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11157(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of IN2014DN11157A publication Critical patent/IN2014DN11157A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF A) and against human angiopoietin 2 (ANG 2) of human IgG1 or IgG4 subclass with mutations I253A H310A and H435A methods for their production pharmaceutical compositions containing said antibodies and uses thereof.
IN11157DEN2014 2012-07-13 2013-07-11 IN2014DN11157A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12176299 2012-07-13
PCT/EP2013/064672 WO2014009465A1 (en) 2012-07-13 2013-07-11 Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

Publications (1)

Publication Number Publication Date
IN2014DN11157A true IN2014DN11157A (en) 2015-10-02

Family

ID=48783248

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11157DEN2014 IN2014DN11157A (en) 2012-07-13 2013-07-11

Country Status (41)

Country Link
US (4) US9695233B2 (en)
EP (2) EP3495387B1 (en)
JP (5) JP6154900B2 (en)
KR (1) KR101774121B1 (en)
CN (1) CN104428315B (en)
AR (2) AR092027A1 (en)
AU (1) AU2013288641B2 (en)
CA (1) CA2874554C (en)
CL (2) CL2015000061A1 (en)
CO (1) CO7151542A2 (en)
CR (1) CR20140542A (en)
CY (2) CY1124681T1 (en)
DK (2) DK2872534T3 (en)
EA (1) EA032192B1 (en)
ES (2) ES2690312T3 (en)
FI (1) FIC20230011I1 (en)
FR (1) FR23C1010I2 (en)
HR (2) HRP20181595T1 (en)
HU (2) HUE056217T2 (en)
IL (1) IL236292B (en)
IN (1) IN2014DN11157A (en)
LT (3) LT2872534T (en)
LU (1) LUC00300I2 (en)
MA (1) MA37794B1 (en)
MX (1) MX361337B (en)
MY (1) MY183712A (en)
NL (1) NL301218I2 (en)
NO (1) NO2023009I1 (en)
NZ (1) NZ702201A (en)
PE (1) PE20150361A1 (en)
PH (1) PH12014502713B1 (en)
PL (2) PL2872534T3 (en)
PT (1) PT2872534T (en)
RS (2) RS57704B1 (en)
SG (1) SG11201408538PA (en)
SI (2) SI2872534T1 (en)
SM (1) SMT202100621T1 (en)
TW (1) TWI506036B (en)
UA (1) UA120029C2 (en)
WO (1) WO2014009465A1 (en)
ZA (1) ZA201408969B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2473565C2 (en) 2006-04-07 2013-01-27 Аерпио Терапетикс, Инк. HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPβ), AND USE THEREOF
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
HK1201178A1 (en) 2011-10-13 2015-08-28 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2013120929A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
AU2013288641B2 (en) 2012-07-13 2017-07-06 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US20140227252A1 (en) 2012-10-31 2014-08-14 Oncomed Pharmaceuticals , Inc. Methods and Monitoring of Treatment with a DLL4 Antagonist
HK1211599A1 (en) 2012-11-08 2016-05-27 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
PL2992010T3 (en) * 2013-04-29 2021-08-23 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
WO2014177460A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
KR20160098239A (en) * 2013-12-13 2016-08-18 에프. 호프만-라 로슈 아게 Spr-based bridging assay for determining the biological activity of multivalent, multispecific molecules
MX380658B (en) 2014-01-15 2025-03-11 Hoffmann La Roche REGION FC VARIANTS WITH ENHANCED PROTEIN A BINDING.
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
WO2015153974A1 (en) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102465120B1 (en) * 2014-07-17 2022-11-10 노보 노르디스크 에이/에스 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
DK3212233T3 (en) 2014-10-31 2020-07-27 Oncomed Pharm Inc COMBINATION THERAPY FOR TREATMENT OF DISEASE
CN107108720A (en) * 2014-11-06 2017-08-29 豪夫迈·罗氏有限公司 Fc region variants and its application method that FCRN with change is combined
AR102522A1 (en) 2014-11-06 2017-03-08 Hoffmann La Roche FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A
HRP20191945T1 (en) 2014-11-07 2020-01-24 Sesen Bio, Inc. IMPROVED IL-6-ANTIBODIES
EP3218399A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use in ophthalmology
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
JP2017534644A (en) * 2014-11-10 2017-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Anti-ANG2 antibody and method of use
RU2017120361A (en) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг ANTIBODIES TO PDGF-B AND WAYS OF THEIR APPLICATION
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AR103477A1 (en) * 2015-01-28 2017-05-10 Lilly Co Eli VEGFA / ANG2 COMPOUNDS
EP4620530A2 (en) 2015-03-20 2025-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to gp120 and their use
EP3328886B1 (en) 2015-07-29 2020-09-16 Allergan, Inc. Heavy chain only antibodies to ang-2
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
CA2998343A1 (en) * 2015-09-14 2017-03-23 Galaxy Biotech Llc Highly potent monoclonal antibodies to angiogenic factors
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
EP4414032A3 (en) 2015-09-23 2024-11-06 EyePoint Pharmaceuticals, Inc. Methods of treating intraocular pressure with activators of tie-2
CN108137681B (en) 2015-09-23 2024-06-18 豪夫迈·罗氏有限公司 Optimized variants of anti-VEGF antibodies
CR20180161A (en) 2015-10-02 2018-05-25 Hoffmann La Roche Bispecific Antibodies for PD1 and TIM3
MY190297A (en) * 2015-10-02 2022-04-12 Hoffmann La Roche Anti-pd1 antibodies and methods of use
WO2017072210A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
US10703810B2 (en) * 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
CN106661117B (en) * 2015-12-30 2020-11-17 深圳先进技术研究院 IgG hybrid anti-TNF alpha and IL-17A bispecific antibodies
KR20250057128A (en) * 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
CN108718522A (en) 2016-02-23 2018-10-30 赛森生物股份有限公司 IL-6 antagonist formulations and application thereof
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6987424B2 (en) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ How to clean and / or disinfect the isolation matrix
EP3455240B1 (en) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017218977A2 (en) * 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
JP6983824B2 (en) * 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft New antibody format
MX2019000727A (en) 2016-07-20 2019-05-02 Aerpio Therapeutics Inc Humanized monoclonal antibodies that target ve-ptp (hptp-ãŸ).
EP3487586A4 (en) * 2016-07-20 2020-03-04 Emory University FORMULAS FOR THE SUPRACHOROIDAL SPACE OF AN EYE AND METHOD
JP7174691B2 (en) 2016-08-23 2022-11-17 メディミューン リミテッド Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
US11059908B2 (en) * 2016-09-29 2021-07-13 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
CN109791149A (en) * 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 The dual combination measuring method based on SPR for functional analysis multispecific molecule
CN108299557A (en) * 2017-01-13 2018-07-20 杭州翰思生物医药有限公司 IgG classes antibody is improved to the binding affinity of FcRn and extends the method for its serum half-life
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
KR20190138636A (en) 2017-03-22 2019-12-13 제넨테크, 인크. Optimized Antibody Compositions for the Treatment of Eye Disorders
SG11201908547VA (en) 2017-03-22 2019-10-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CA3053357A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
CN110799546B (en) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 Recombinant bispecific antibody
WO2019122054A1 (en) * 2017-12-22 2019-06-27 F. Hoffmann-La Roche Ag Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
CN110283248B (en) * 2018-01-05 2020-07-28 百奥泰生物制药股份有限公司 Long-acting low-toxicity recombinant anti-VEGF humanized monoclonal antibody and production method thereof
CN111699004A (en) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 Treatment of ophthalmic disorders
JP2021514656A (en) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． IL-6 antibody and its fusion constructs and conjugates
CN110305210B (en) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 Novel antibody molecules, methods of making and uses thereof
MY206833A (en) 2018-04-02 2025-01-09 Bristol Myers Squibb Co Anti-trem-1 antibodies and uses thereof
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
CN112912104A (en) * 2018-08-17 2021-06-04 三钰生物科技股份有限公司 Anti-angiogenesis fusion protein and application thereof
CN120058958A (en) 2018-09-24 2025-05-30 视点制药公司 Multispecific antibodies targeting HPTP-beta (VE-PTP) and VEGF
CN119033685A (en) * 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 Antibody formulations
CR20210332A (en) 2018-12-21 2021-09-09 Hoffmann La Roche Antibody that binds to vegf and il-1beta and methods of use
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
CA3138682A1 (en) 2019-04-29 2020-11-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
JP2022537338A (en) 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー Methods for generating bivalent bispecific antibody-expressing cells by targeted integration of multiple expression cassettes of defined configuration
AU2020294878A1 (en) 2019-06-19 2021-12-23 F. Hoffmann-La Roche Ag Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020326243A1 (en) * 2019-08-06 2022-02-17 F. Hoffmann-La Roche Ag Personalized treatment of ophthalmologic diseases
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7735291B2 (en) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド Nectin-4 antibody conjugates and uses thereof
CN115551529A (en) * 2020-02-28 2022-12-30 西北大学 Methods for enhancing aqueous humor outflow and lowering intraocular pressure
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4126949A1 (en) 2020-03-24 2023-02-08 Genentech, Inc. Tie2-binding agents and methods of use
CN115397850A (en) 2020-03-30 2022-11-25 豪夫迈·罗氏有限公司 Antibodies that bind to VEGF and PDGF-B and methods of use thereof
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
JP2023533173A (en) 2020-07-09 2023-08-02 エフ． ホフマン－ラ ロシュ アーゲー Concentrated compositions of proteins, their preparation and their use
JP7158626B1 (en) * 2020-09-04 2022-10-21 エフ．ホフマン－ラ ロシュ アーゲー Antibodies that bind to VEGF-A and ANG2 and methods of use
WO2022057888A1 (en) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Bispecific antigen binding molecule specifically binding to vegf and ang-2
CN116390767A (en) 2020-10-15 2023-07-04 基因泰克公司 Hyaluronic acid binding derivatives of multifunctional proteoglycans (VG 1) for long-acting delivery of therapeutic agents
KR20230162791A (en) * 2021-03-30 2023-11-28 에이비프로 코퍼레이션 Method for treating choroidal neovascularization using anti-ANG2 x VEGF multispecific antibodies
WO2022226539A1 (en) * 2021-04-23 2022-10-27 Immunome, Inc. Methods of administering antibodies against sars-cov-2 spike protein
EP4349861A4 (en) * 2021-06-04 2025-07-23 Innovent Biologics Suzhou Co Ltd BISPECIFIC BINDING MOLECULE FOR BINDING VEGF AND ANG2 AND USE THEREOF
TW202322850A (en) * 2021-08-05 2023-06-16 美商美國禮來大藥廠 Antibody optimization
JP2024534159A (en) * 2021-08-23 2024-09-18 アビラマックス・バイオファーマ・インコーポレイテッド Compositions and methods for transgene expression
CN116265487B (en) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 Anti-ANG 2-VEGF bispecific antibodies and uses thereof
CN116925234B (en) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 AAV vector for encoding anti-VEGF-A and ANG-2 bispecific antibody
WO2024065268A1 (en) * 2022-09-28 2024-04-04 科兴生物制药股份有限公司 Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2
EP4628097A1 (en) 2022-12-01 2025-10-08 Innovent Biologics (Suzhou) Co., Ltd. Preparation containing bispecific binding molecule binding to vegf and ang2 and use thereof
WO2024220873A1 (en) * 2023-04-21 2024-10-24 Emory University Asymmetric antibody glycosylation methods and compositions related thereto

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4490473A (en) 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4752601A (en) 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0359096B1 (en) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
FI903489A7 (en) 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5364930A (en) 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
US5419904A (en) 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE4137512A1 (en) 1991-11-15 1993-05-19 Henkel Kgaa DISPERSION-BASED HOT SEAL COATING
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994008027A1 (en) 1992-09-28 1994-04-14 Midwest Research Institute Fermentation of cellulose and hemicellulose in corn fiber and distillers dried grains with solubles to ethanol
ATE215565T1 (en) 1992-10-28 2002-04-15 Genentech Inc USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5412468A (en) 1993-03-09 1995-05-02 The Perkin-Elmer Corporation Grouping of spectral bands for data acquisition in a spectrophotometer
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
DE69633973T2 (en) 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. ANTIBODIES TO THE ALPHA CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
DE19533718A1 (en) 1995-09-12 1997-03-13 Basf Ag Process for the hydrogenation of aromatic compounds in which at least one amino group is bonded to an aromatic nucleus
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE69726003T2 (en) 1996-07-16 2004-08-26 Andreas Plückthun IMMUNGLOBULIN SUPERFAMILY DOMAINS AND FRAGMENTS WITH INCREASED SOLUBILITY
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
AU729158B2 (en) 1997-01-31 2001-01-25 Genentech Inc. O-fucosyltransferase
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6323321B1 (en) 1997-03-05 2001-11-27 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibody 97A6
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (en) 1997-04-07 2005-07-16 Genentech, Inc. ANTI-VEGF ANTIBODIES.
SI0973804T1 (en) 1997-04-07 2007-06-30 Genentech Inc Anti-vegf antibodies
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE19721700C1 (en) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutant OKT3 antibody
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US20040191256A1 (en) 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (en) 1997-12-05 2012-01-30 Scripps Research Inst Humanization of murine antibody
ATE283364T1 (en) 1998-01-23 2004-12-15 Vlaams Interuniv Inst Biotech MULTIPURPOSE ANTIBODIES DERIVATIVES
CN1204147C (en) 1998-02-25 2005-06-01 利思进药品公司 Methods of increasing the circulating half-life of antibody-based fusion proteins
ES2292236T3 (en) 1998-04-02 2008-03-01 Genentech, Inc. VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE19819846B4 (en) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
AU1687500A (en) 1998-12-16 2000-07-03 Kyowa Hakko Kogyo Co. Ltd. Antihuman vegf monoclonal antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
AU2940900A (en) 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ECSP992970A (en) 1999-06-01 2000-01-27 SEQUENCE OF THE GENE RELATED TO ANGIOPOYETINO SCARFACE 3
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 How to regulate transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60039448D1 (en) 1999-10-29 2008-08-21 Genentech Inc AGAINST PROSTATE-STATE-TEMPORARY (PSCA) ANTIBODIES AND THEIR USE
JP2003516755A (en) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
NZ518764A (en) 1999-12-29 2004-02-27 Immunogen Inc Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
PT1270595E (en) 2000-03-03 2008-09-16 Kyowa Hakko Kogyo Kk Anti ccr4 antibody and its fragment
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
KR20020093029A (en) 2000-04-11 2002-12-12 제넨테크, 인크. Multivalent Antibodies And Uses Therefor
FR2807767B1 (en) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement MONOCLONAL ANTIBODIES ANTI-D
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060024304A1 (en) 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
EA013563B1 (en) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. A transgenic non-human animal, producing antibodies with modified sugar chains, a process for producing antibodies composition and a medicament comprising the antibodies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (en) 2000-11-30 2013-06-04 Medarex, Inc. Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal mice zadas
ES2727425T3 (en) 2000-12-12 2019-10-16 Medimmune Llc Molecules with prolonged half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4524074B2 (en) 2001-03-09 2010-08-11 アーナソン， バリー ジー． Polymeric immunoglobulin fusion proteins targeting low affinity Fcγ receptors
CA2440831C (en) 2001-04-02 2013-05-28 Genentech, Inc. Combination therapy using cd40 and cd20 ligands
CN1561345B (en) 2001-04-13 2011-09-14 比奥根艾迪克Ma公司 Antibodies against VLA-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
GB0118662D0 (en) 2001-07-31 2001-09-19 Univ Southampton Binding agents
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1427829A4 (en) 2001-08-31 2005-10-12 Abmaxis Inc Multivalent protein conjugate with multiple ligand-binding domains of receptors
ES2276735T3 (en) 2001-09-14 2007-07-01 Affimed Therapeutics Ag SINGLE CHAIN MULTIMERIC FV ANTIBODIES IN TANDEM.
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
PL213948B1 (en) 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20060034829A1 (en) 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US20080206242A1 (en) 2002-03-01 2008-08-28 Xencor, Inc. Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US20070148171A1 (en) 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080152649A1 (en) 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JPWO2003085119A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for enhancing binding activity of antibody composition to Fcγ receptor IIIa
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION APPROPRIATE TO PATIENT SUFFERING FROM POLYMORPHISM FC gammma RIIIA
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2003232081B2 (en) 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
US20060062727A1 (en) 2002-07-09 2006-03-23 Philips Heidi S Compositions and methods for the diagnosis and treatment of tumor
CA2492447A1 (en) 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
CN101987871A (en) 2002-09-27 2011-03-23 赞科股份有限公司 Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ATE480562T1 (en) 2002-10-15 2010-09-15 Facet Biotech Corp CHANGE IN FCRN BINDING AFFINITIES OR SERUM HALF-LIFE TIMES OF ANTIBODIES USING MUtagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
JP2006524039A (en) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. Treatment with anti-vegf antibodies
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
CN100518817C (en) * 2003-07-04 2009-07-29 南加州大学 Therapeutic agent to recover hematopoiesis function and its compositions and usage
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CN1871259A (en) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
JP4890253B2 (en) 2003-10-09 2012-03-07 アンブレツクス・インコーポレイテツド Azide or acetylene-terminated water-soluble polymer
JP2007531707A (en) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
DE602004026470D1 (en) 2003-11-05 2010-05-20 Roche Glycart Ag FC RECEPTOR AND EFFECTOR FUNCTION
EP3858387A1 (en) 2003-11-06 2021-08-04 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20050142133A1 (en) 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
BRPI0417107A (en) 2003-12-19 2007-02-06 Genentech Inc antibody fragment, antibody fragment preparation methods, isolated nucleic acid, compositions, host cell, and antibody fragment manufacture and generation methods
US20050136051A1 (en) 2003-12-22 2005-06-23 Bernard Scallon Methods for generating multimeric molecules
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
NZ548785A (en) 2004-01-07 2011-08-26 Novartis Vaccines & Diagnostic M-CSF-Specific monoclonal antibody and uses thereof
US20060018911A1 (en) 2004-01-12 2006-01-26 Dana Ault-Riche Design of therapeutics and therapeutics
US7118999B2 (en) 2004-01-16 2006-10-10 International Business Machines Corporation Method and apparatus to increase strain effect in a transistor channel
JP4987484B2 (en) 2004-01-22 2012-07-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anticancer antibodies with reduced complement binding
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
CN1961003B (en) 2004-03-31 2013-03-27 健泰科生物技术公司 Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
PL1737891T3 (en) 2004-04-13 2013-08-30 Hoffmann La Roche Anti-p-selectin antibodies
US20050276806A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JP2008512352A (en) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド Novel tetravalent bispecific antibody
MX2007001345A (en) 2004-08-04 2008-03-11 Applied Molecular Evolution Variant fc regions.
ZA200701715B (en) 2004-08-19 2008-07-30 Genentech Inc Polypeptide variants with altered effector function
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
RU2412200C2 (en) 2004-11-12 2011-02-20 Ксенкор, Инк. Fc-VERSIONS WITH CHANGED BINDING WITH FcRn
KR101017301B1 (en) 2004-12-21 2011-02-28 메드임뮨 리미티드 Antibodies to Angiopoietin-2 and Uses thereof
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
DOP2006000029A (en) 2005-02-07 2006-08-15 Genentech Inc ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
CN101218251A (en) 2005-02-28 2008-07-09 森托科尔公司 Heterodimeric protein binding compositions
JP4743388B2 (en) 2005-03-18 2011-08-10 栗田工業株式会社 Disposal method of waste water containing photoresist
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2006324477A1 (en) 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
AR059432A1 (en) 2006-02-10 2008-04-09 Genentech Inc ANTI-FGF19 ANTIBODIES AND METHODS USING THESE
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009536527A (en) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド Binding polypeptide with optimized scaffold
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US7935796B2 (en) 2006-12-08 2011-05-03 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3
KR20140148491A (en) 2006-12-19 2014-12-31 제넨테크, 인크. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AU2008208288B2 (en) 2007-01-24 2014-04-03 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
MX2010001637A (en) 2007-08-17 2010-03-15 Hoffmann La Roche CYTOTOXICITY MEDIATION OF CELLS THAT AVOID THE SURFACE EXPRESSION OF CD9.
CN101842116A (en) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 Compositions binding multiple epitopes of IGF-1R
KR20100085067A (en) 2007-09-28 2010-07-28 추가이 세이야쿠 가부시키가이샤 Anti-glypican-3 antibody having improved kinetics in plasma
TWI554517B (en) 2007-10-30 2016-10-21 建南德克公司 Antibody purification by cation exchange chromatography
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
CA2706419A1 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs binding il-13
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL2235064T3 (en) 2008-01-07 2016-06-30 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
BRPI0907735B1 (en) 2008-02-08 2021-10-05 Astrazeneca Ab MODIFIED IGG-CLASS MONOCLONAL ANTIBODY SPECIFIC TO IFNAR1, ISOLATED NUCLEIC ACID AND PHARMACEUTICAL COMPOSITION
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2009142460A2 (en) 2008-05-23 2009-11-26 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
JP6146949B2 (en) * 2008-06-20 2017-06-21 ノバルティス アーゲー Immunoglobulin with reduced aggregation
HRP20170615T1 (en) 2008-06-25 2017-07-28 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
ES2628108T3 (en) 2008-09-03 2017-08-01 F. Hoffmann-La Roche Ag Multispecific Antibodies
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
ES2828721T3 (en) 2008-10-14 2021-05-27 Genentech Inc Immunoglobulin variants and their uses
PT4209510T (en) 2008-12-09 2024-04-02 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
MX2011013781A (en) 2009-06-17 2012-05-29 Abbott Biotherapeutics Corp ANTI-VEGF ANTIBODIES AND ITS USES.
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
UY32920A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int BISPECIFIC UNION MOLECULES FOR ANTI-ANGIOGENESIS THERAPY
UA114277C2 (en) 2010-02-23 2017-05-25 Дженентек, Інк. Anti-angiogenesis therfpy for the treatment of ovarian cancer
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CN102958538A (en) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 Compositions and methods useful for reducing the viscosity of protein-containing formulations
US8377337B2 (en) 2010-05-04 2013-02-19 Sabic Innovative Plastics Ip B.V. Method of incorporating an additive into a polyamide-poly(arylene ether) composition, composition prepared thereby, and article comprising the composition
CN102191209A (en) * 2010-08-26 2011-09-21 苏州大学 VEGF165 and Ang-1 double-gene co-expression vector and application thereof
SG193554A1 (en) 2011-03-29 2013-11-29 Roche Glycart Ag Antibody fc variants
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
CN102250248A (en) 2011-06-15 2011-11-23 常州亚当生物技术有限公司 Anti-VEGF/ANG2 bispecific antibody, and application thereof
CN102250247B (en) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 Bispecific antibody to VEGF/ANG2 and application thereof
CN102453577A (en) 2011-09-21 2012-05-16 李国庆 Novel coal slime composite fuel and preparation method thereof
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
CN104271601B (en) 2012-05-31 2020-02-04 霍夫曼-拉罗奇有限公司 Methods of treating cancer using PD-1 axis binding antagonists and VEGF antagonists
AU2013288641B2 (en) 2012-07-13 2017-07-06 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

Also Published As

Publication number Publication date
RS62509B1 (en) 2021-11-30
AU2013288641A1 (en) 2014-12-11
CA2874554A1 (en) 2014-01-16
IL236292B (en) 2020-06-30
CL2017002146A1 (en) 2018-04-13
ES2690312T3 (en) 2018-11-20
MX2014015518A (en) 2015-06-23
EP3495387B1 (en) 2021-09-01
LT3495387T (en) 2021-11-25
HK1206365A1 (en) 2016-01-08
US20140017244A1 (en) 2014-01-16
CL2015000061A1 (en) 2015-05-08
JP7280859B2 (en) 2023-05-24
CY2023005I1 (en) 2023-06-09
JP2015527064A (en) 2015-09-17
PT2872534T (en) 2018-10-26
MY183712A (en) 2021-03-09
TW201406782A (en) 2014-02-16
CY1124681T1 (en) 2022-07-22
FIC20230011I1 (en) 2023-02-13
ES2896493T3 (en) 2022-02-24
NL301218I1 (en) 2023-02-15
JP2020062036A (en) 2020-04-23
PH12014502713A1 (en) 2015-02-02
JP6640319B2 (en) 2020-02-05
ZA201408969B (en) 2019-04-24
US9695233B2 (en) 2017-07-04
NL301218I2 (en) 2023-04-04
HRP20211641T1 (en) 2022-02-04
LTPA2023507I1 (en) 2023-03-10
IL236292A0 (en) 2015-02-26
LT2872534T (en) 2018-10-25
KR101774121B1 (en) 2017-09-01
EA032192B1 (en) 2019-04-30
SI2872534T1 (en) 2018-11-30
CA2874554C (en) 2019-12-03
SI3495387T1 (en) 2021-12-31
NO2023009I1 (en) 2023-02-14
PH12014502713B1 (en) 2019-11-29
MA37794A1 (en) 2016-03-31
PL3495387T3 (en) 2022-01-10
HUS2300008I1 (en) 2023-02-28
MX361337B (en) 2018-12-04
CR20140542A (en) 2015-02-12
AR092027A1 (en) 2015-03-18
EP2872534B1 (en) 2018-08-08
EP2872534A1 (en) 2015-05-20
LUC00300I2 (en) 2025-09-22
CN104428315A (en) 2015-03-18
SG11201408538PA (en) 2015-02-27
KR20150023688A (en) 2015-03-05
US20210095013A1 (en) 2021-04-01
MA37794B1 (en) 2017-07-31
JP6462750B2 (en) 2019-01-30
CO7151542A2 (en) 2014-12-29
UA120029C2 (en) 2019-09-25
PE20150361A1 (en) 2015-03-14
SMT202100621T1 (en) 2022-01-10
DK2872534T3 (en) 2018-10-22
LTC2872534I2 (en) 2024-10-25
HRP20181595T1 (en) 2018-12-14
JP2021036888A (en) 2021-03-11
PL2872534T3 (en) 2018-12-31
JP6796184B2 (en) 2020-12-02
NZ702201A (en) 2018-01-26
AR124240A2 (en) 2023-03-01
FR23C1010I1 (en) 2023-04-14
DK3495387T3 (en) 2021-11-08
WO2014009465A1 (en) 2014-01-16
AU2013288641B2 (en) 2017-07-06
CN104428315B (en) 2017-09-29
CY2023005I2 (en) 2023-06-09
FR23C1010I2 (en) 2024-04-05
JP2019062905A (en) 2019-04-25
RS57704B1 (en) 2018-12-31
HUE056217T2 (en) 2022-02-28
EP3495387A1 (en) 2019-06-12
US20230212277A1 (en) 2023-07-06
TWI506036B (en) 2015-11-01
JP2017140038A (en) 2017-08-17
US20170260265A1 (en) 2017-09-14
JP6154900B2 (en) 2017-06-28
EA201500132A1 (en) 2015-08-31
US10683345B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
IN2014DN11157A (en)
EP3327038A3 (en) Bispecific her2 antibodies and methods of use
IL291613A (en) Inhibitory anti-factor xii/fxiia monoclonal antibodies, method of producing the same, pharmaceutical composition containing the same and medical uses
MX356337B (en) Antibodies against human csf-1r and uses thereof.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
PH12012501830A1 (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2020004503A (en) Humanized or chimeric cd3 antibodies.
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MX340558B (en) Bispecific antibodies comprising a disulfide stabilized - fv fragment.
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
BR112014019116A2 (en) KIT, PHARMACEUTICAL COMPOSITION, Biospecific Antibody Molecules, METHODS OF TREATMENT OF A DISEASE AND PRODUCTION OF A BISPECIFIC ANTIBODY, VECTOR AND HOSPED CELL
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX2012002458A (en) Humanized anti-cdcp1 antibodies.
EA201590161A1 (en) COMPOSITIONS OF ETHANRECEPT DIFFERENTLY DIFFERENT BY REDUCTION OF PARTICLES OF A REVERSIBLE RANGE
MX2013006875A (en) Anti-notch1 antibodies.
MX2014002996A (en) Bispecific anti-egfr/anti igf-1r antibodies.
PH12015501360A1 (en) Bmp-6 antibodies
IN2015DN00645A (en)
EA201300138A1 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING PRODUCTS OR ENHANCEMENT OF ELIMINATION OF PROTEIN P24
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
IN2014DN03010A (en)
UA110051C2 (en) Normal;heading 1;heading 2;heading 3;ANTIBODY THAT BINDS TGF-ALPHA AND EPIREGULIN